<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">

First Stable, Serially Transplantable M5 AML PDX Model

Patient-derived xenografts (PDX) have proven to be useful preclinical research tools across many cancer types. However, for acute myeloid leukemia (AML), establishing a stable and serially transplantable AML model has proven particularly difficult, due to low take rate, low-level engraftment, instability, incapability of serial transplantation, and absence of symptoms.